伊朗人群中华法林治疗与 CYP2C9 和 VKORC1 基因多态性的关联
Association of Warfarin Therapy with and Genes Polymorphism in Iranian Population.
作者信息
Rafiee Sajad, Rajabibazl Masoumeh, Meshkani Reza, Daraei Azam, Zargari Mehryar, Sharafeddin Fahimeh, Fazeli Zahra, Toffani Milani Attabak, Taherkhani Maryam
机构信息
Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Iran J Pharm Res. 2017 Summer;16(3):1230-1237.
Warfarin is a vitamin K antagonist that genetic and non-genetic factors affected on its dose requirement in the patients with cardio vascular disease. The aim of this study was whether the and polymorphisms influence on warfarin dose requirements in the part of Iranian patients. Blood samples were collected from 86 warfarin-treated patients. After extraction of genomic DNA, the (rs9923231) and the (rs429358 and rs7412) polymorphisms were genotyped by PCR-RFLP technique. We found that the Iranian patients carrying genotypes GA or AA of polymorphism tended to receive lower dose of warfarin (p = 0.018). Furthermore, the E3/E3 genotype was observed with the frequency more than 60% in the patients with low dose of warfarin. The BMI and weight also showed a positive correlation with warfarin dose. However, it was not statistically significant (p > 0.05). The results of this study may be useful in defining of warfarin dose algorithms for Iranian patients.
华法林是一种维生素K拮抗剂，遗传和非遗传因素会影响心血管疾病患者对其的剂量需求。本研究的目的是探讨[具体基因名称1]和[具体基因名称2]多态性是否会影响部分伊朗患者对华法林的剂量需求。从86名接受华法林治疗的患者中采集血样。提取基因组DNA后，采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）技术对[具体基因名称1]（rs9923231）和[具体基因名称2]（rs429358和rs7412）多态性进行基因分型。我们发现，携带[具体基因名称1]多态性GA或AA基因型的伊朗患者倾向于接受较低剂量的华法林（p = 0.018）。此外，在低剂量华法林治疗的患者中，E3/E3基因型的出现频率超过60%。体重指数（BMI）和体重也与华法林剂量呈正相关。然而，差异无统计学意义（p > 0.05）。本研究结果可能有助于为伊朗患者确定华法林剂量算法。
Zotero 插件